OncoLab Co. Ltd.
- Biotech or pharma, therapeutic R&D
- Biotech or pharma, animal health
OncoLab Co., Ltd. is a biotechnology company developing breakthrough technology that bridges the gap between immunotherapy and precision drug delivery.
Our proprietary ANGel platform is a bioresponsive hydrogel-based nanogel delivery system designed for subcutaneous injection near disease sites, offering sustained release and long-lasting therapeutic effects. By attaching antibodies, peptides, or small molecules to the nanogel surface, ANGel enables targeted delivery to the tumor microenvironment and immune cells with high precision and safety.
Our lead indication is triple-negative breast cancer (TNBC), where preclinical studies have demonstrated complete remission in approximately 50% of treated subjects. We have accumulated extensive in-house data supporting the efficacy, safety, and platform versatility of ANGel, positioning OncoLab for rapid clinical translation and global partnerships.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}